可载药栓塞微球加载伊立替康经肝动脉治疗伊
2017-7-30 来源：不详 浏览次数：次可载药栓塞微球加载伊立替康（DEBIRI）经肝动脉治疗伊立替康全身化疗失败的不可切除结直肠癌肝转移患者的临床疗效和安全性
AbstractIntroduction：Responseratestosystemicchemotherapyforpatientswhohavefailedirinotecan-basedchemotherapyforliver-dominantmetastaticcolorectalcancerrangebetween10and18%withoverallsurvivalbetween7and9
months.Theaimofthisstudywastoassesstheefficacyandsafetyofhepaticarterialirinotecantherapyinpatientswithhepatic-dominantmetastaticcolorectalcancerwhohadfailedsystemicirinotecan.
摘要
介绍：基于伊立替康化疗失败的结直肠癌肝转移患者，其全身化疗的肿瘤缓解率仅为10%-18%，总生存期为7-9个月。本研究旨在评估可载药栓塞微球加载伊立替康（DEBIRI）经肝动脉治疗伊立替康全身化疗失败的结直肠癌肝转移患者的临床疗效及安全性。
MethodsThiswasamulti-institutional,multi-national,analysisofpatientswhoreceivedDEBIRIinthesettingofunresectableliver-dominantmetastaticcolorectalcancer.Patientshadreceivedbetween1and4linesofprior
chemotherapy,themajorityofwhichincludedsystemicirinotecan.Primaryendpointsweretoxicityprofileandtumorresponserate.
方法：本研究是一项多国、多中心的研究，是对可载药栓塞微球加载伊立替康（DEBIRI）治疗不可切除结直肠癌肝转移患者进行分析。患者既往已经接受过1-4种的化疗方案的治疗，大多数方案包含全身的伊立替康化疗。主要的疗效终点观察肿瘤应答情况与肝脏的毒性。
ResultspatientswithunresectablelivermetastaseswhohadundergoneDEBIRItreatmentswerereviewed.treatmentswereperformedinpatientswhohadreceivedpriorsystemicirinotecan.treatmentswereperformedinirinotecan-na?¨vepatients.ThemediannumberofDEBIRItreatmentswas1(range1–8);mediantreatmentdosewasmg(range50–mg),withtotalhepatictreatmentofapproximatelymg(range20/30–/mg).All-gradeadverseeventsoccurredin18%ofpatientsreceivingpriorsystemicirinotecan海南白癜风医院哪里白癜风能治愈
